Cargando…
Increased Secretory Leukocyte Protease Inhibitor (SLPI) Production by Highly Metastatic Mouse Breast Cancer Cells
The precise molecular mechanisms enabling cancer cells to metastasize from the primary tumor to different tissue locations are still largely unknown. Secretion of some proteins by metastatic cells could facilitate metastasis formation. The comparison of secreted proteins from cancer cells with diffe...
Autores principales: | Sayers, Kevin T., Brooks, Alan D., Sayers, Thomas J., Chertov, Oleg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128660/ https://www.ncbi.nlm.nih.gov/pubmed/25110884 http://dx.doi.org/10.1371/journal.pone.0104223 |
Ejemplares similares
-
Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
por: Dickey, Brittney L., et al.
Publicado: (2021) -
Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.
por: Nyström, M, et al.
Publicado: (1999) -
Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression
por: Wex, Thomas, et al.
Publicado: (2011) -
Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers
por: Kozin, Sergey V., et al.
Publicado: (2017) -
Secretory Leukocyte Protease Inhibitor (SLPI) Is, like Its Homologue Trappin-2 (Pre-Elafin), a Transglutaminase Substrate
por: Baranger, Kévin, et al.
Publicado: (2011)